EXAI vs. RXRX

Last updated Jun 4, 2026

EXAI (Exscientia Ltd ADR) and RXRX (Recursion Pharmaceuticals, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. At a 0.38 correlation, their price movements are largely independent.

Performance

EXAI vs. RXRX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Exscientia Ltd ADR (EXAI) and Recursion Pharmaceuticals, Inc. (RXRX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

EXAI

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

RXRX

• 1D: -3.88%
• 1M: -1.42%
• YTD: -15.16%
• 6M: -25.54%
• 1Y: -20.96%
• 3Y*: -25.01%
• 5Y*: -34.79%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

EXAI vs. RXRX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
EXAI Exscientia Ltd ADR	0.00%	0.00%	-24.49%	20.26%	-73.03%	-27.08%
RXRX Recursion Pharmaceuticals, Inc.	-15.16%	-39.50%	-31.44%	27.89%	-54.99%	-21.64%

Correlation

The correlation between EXAI and RXRX is 0.38, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (3Y) Calculated over the trailing 3-year period	0.39
Correlation (All Time) Calculated using the full available price history since Oct 4, 2021	0.38

Fundamentals

Total Revenue (TTM) EXAI : $17.07M RXRX : $66.29M
Gross Profit (TTM) EXAI : -$11.56M RXRX : -$22.83M
EBITDA (TTM) EXAI : -$135.58M RXRX : -$505.90M

Return for Risk

EXAI vs. RXRX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RXRX

RXRX Risk / Return Rank: 29
RXRX Sharpe Ratio Rank: 28
RXRX Sortino Ratio Rank: 31
RXRX Omega Ratio Rank: 31
RXRX Calmar Ratio Rank: 28
RXRX Martin Ratio Rank: 29

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EXAI vs. RXRX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Exscientia Ltd ADR (EXAI) and Recursion Pharmaceuticals, Inc. (RXRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	EXAI	RXRX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	-0.29	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	—	-0.37	—
Sharpe Ratio (All Time) Calculated using the full available price history	—	-0.37	—

Drawdowns

Drawdown Indicators

	EXAI	RXRX	Difference
Max Drawdown Largest peak-to-trough decline	—	-93.13%	—
Max Drawdown (1Y) Largest decline over 1 year	—	-58.17%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-82.09%	—
Max Drawdown (5Y) Largest decline over 5 years	—	-93.13%	—
Current Drawdown Current decline from peak	—	-91.60%	—
Average Drawdown Average peak-to-trough decline	—	-75.35%	—
Ulcer Index Depth and duration of drawdowns from previous peaks	—	35.17%	—

Volatility

Volatility by Period

	EXAI	RXRX	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	18.83%	—
Volatility (6M) Calculated over the trailing 6-month period	—	44.57%	—
Volatility (1Y) Calculated over the trailing 1-year period	—	73.43%	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	—	93.48%	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	—	93.60%	—

Dividends

EXAI vs. RXRX - Dividend Comparison

Neither EXAI nor RXRX has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both EXAI and RXRX in my portfolio?

EXAI and RXRX have a correlation of 0.38, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.